VarmX to Present New Data at the 2022 ISTH Congress

Preclinical data package details pharmacology and
safety of VMX-C001, VarmX’s lead compound

First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001

• Trial will assess safety, tolerability, PK and PD of VMX-C001
• Major corporate milestone achieved as VarmX transitions into a clinical-stage company

VarmX awarded funding from the EIC Accelerator

Leiden, The Netherlands, 21 October 2021 - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has been awarded up to €17.5 million from the European Innovation Council (EIC) Accelerator.

VarmX to Present New Data on Lead Compound, VMX-C001, at the ISTH 2021 Virtual Congress

Leiden, The Netherlands, 19 July 2021 - VarmX today announces that new preclinical data on VMX-C001 has been selected to be presented during an oral presentation at the ISTH (International Society on Thrombosis and Haemostasis) Virtual Congress on Tuesday, 20 July, 2021 at 11.00-12.00 EDT.

VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board

VarmX announces the appointment of Dr. Jan Öhrström, as Chief Executive Officer, and of Dr. Alex Gold to the Supervisory Board.

VarmX appoints Dr. Gerard Short as Chief Medical Officer

VarmX raises € 32 million series B financing

VarmX raises € 12.5 million to develop VMX-COO1

Funding enables clinical stage trials of lead compound VMX-COO1.

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

VarmX announces publication in Nature Communications of groundbreaking snake venom inspired approach to restore blood clotting in patients using anticoagulants.

VarmX raises seed capital for development of VMX-C001

Restoring blood clotting in patients using anticoagulants.

This website uses functional and analytical cookies. Accept Deny